The UK and US have established a key trade agreement that will maintain no levies on UK medicine exports being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This pledge secures that tariffs on these key exports will remain at nothing for a timeframe of the next three years.
This agreement comes after earlier warnings to dramatically increase duties on branded pharmaceutical imports, with increases floated reaching one hundred percent.
"This agreement between the Britain strengthens the international landscape for innovative medicines and introduces long-overdue balance to American-British medicine commerce," an announcement declared.
Economic Importance
Medicines are one of the UK's most significant goods shipped to the America, which is easily the largest destination for large British pharmaceutical firms.
Statistics show that in the year leading up to the third quarter, the UK sold medicines totaling £11.1bn to the US. This amount made up a significant portion of total UK exports in that period.
"This deal secures jobs, stimulates investment and facilitates the UK to emerge as a international leader for biotech and pharma," a minister commented.
Detailed NHS Changes
The agreement involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. Previously, repayments were more than 20%.
Recent Tensions
The deal follows a long-running row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
The disagreement were heightened by arguments that US patients were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been paused or scrapped, while substantial expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
